Trial Profile
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine/tenofovir alafenamide; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ADVANCE
- 22 Feb 2023 Results(n=159) assessing changes in weight, lipids, glucose and HBA1C after switch from their original randomized treatment (ADVANCE trial) to TDF/3TC/DTG in the CHARACTERISE trial presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
- 15 Dec 2022 Results of a substudy CHARACTERISE (n=172) published in the Clinical Infectious Diseases
- 26 Oct 2022 Results from DolPHIN-2, ADVANCE, NAMSAL and VISEND, comparing rates of virological failure (VF)and re-suppression in four randomised trials of dolutegravir (DTG), efavirenz (EFV) and protease inhibitors , presented at the 16th International Congress on Drug Therapy and HIV Infection